MedPath

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1
Active, not recruiting
Conditions
Triple Negative Breast Cancer
Endometrial Cancer
Gastric Cancer
Renal Cell Carcinoma
Castration-resistant Prostate Cancer
Colorectal Cancer
Differentiated Thyroid Cancer
Ovarian Cancer
Lower Esophageal Cancer
Urothelial Carcinoma
Interventions
Drug: atezolizumab
Drug: cabozantinib
Registration Number
NCT03170960
Lead Sponsor
Exelixis
Brief Summary

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Detailed Description

* Dose Escalation Stage: to determine the schedule and maximum tolerated dose (MTD) and/or recommended Expansion Stage dose of cabozantinib when taken in combination with a standard dosing regimen of atezolizumab (1200 mg infusion, once every 3 weeks).

* Expansion Stage: to determine the preliminary efficacy (objective response rate \[ORR\] per RECIST 1.1) and safety of the recommended combination dose of cabozantinib with atezolizumab in eighteen tumor-specific cohorts including subjects with advanced UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H\&N, and DTC.

* Exploratory SAC Cohorts: Descriptive efficacy, safety, PK, and biomarker analyses of single-agent cabozantinib in UC, NSCLC, and CRPC subjects. Descriptive efficacy and safety analyses of combination therapy after progression on single-agent therapy

* Exploratory SAA Cohort: Descriptive efficacy, safety, PK, and biomarker analyses of single-agent atezolizumab in CRPC subjects. Descriptive efficacy and safety analyses of combination therapy after progression on single-agent therapy

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
1732
Inclusion Criteria

  1. Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:

    • Dose-Escalation Stage:

      • Subjects with UC (including renal pelvis, ureter, bladder, urethra) after prior platinum-based therapy, or
      • Subjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapy

    • Expansion Stage:

      • Inoperable locally advanced or metastatic solid tumor (UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H&N cancer, and DTC as outlined above)

  2. Measurable disease per RECIST 1.1 as determined by the investigator.

  3. Tumor tissue material available (archival or recent tumor biopsy)

  4. Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.

  5. Age eighteen years or older on the day of consent.

  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

  7. Adequate organ and marrow function.

  8. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.

  9. Female subjects of childbearing potential must not be pregnant at screening.

Read More
Exclusion Criteria
  1. Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5, 7, 9, 11, 17, 19 and 20. Other restrictions regarding prior therapy may apply.
  2. Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 4 weeks before first dose of study treatment.
  3. Concomitant anticoagulation with oral anticoagulants.
  4. Subject is receiving systemic steroid therapy (>10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
  5. Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
  6. The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of autoimmune disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV), AIDS-related illness, acute or chronic hepatitis B or C infection, positive test for tuberculosis, moderate to severe hepatic impairment (Child-Pugh B or C).
  7. Pregnant or lactating females.
  8. Previously identified allergy or hypersensitivity to components of the study treatment formulations.
  9. Diagnosis of another malignancy within 2 years before first dose of study treatment.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Expansion Cohort 1cabozantinibRCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
Expansion Cohort 6atezolizumabCRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
Expansion Cohort 7cabozantinibStage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
Expansion Cohort 23atezolizumabMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
Expansion Cohort 10cabozantinibRCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
Expansion Cohort 5cabozantinibUC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
Expansion Cohort 13atezolizumabEC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
Expansion Cohort 13cabozantinibEC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
Expansion Cohort 16cabozantinibCRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
Expansion Cohort 8atezolizumabStage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
Dose EscalationcabozantinibSubjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard "3 plus 3" design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage.
Dose EscalationatezolizumabSubjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard "3 plus 3" design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage.
Expansion Cohort 1atezolizumabRCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
Expansion Cohort 2atezolizumabUC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
Expansion Cohort 3atezolizumabUC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
Expansion Cohort 2cabozantinibUC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
Expansion Cohort 3cabozantinibUC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
Expansion Cohort 4atezolizumabUC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
Expansion Cohort 4cabozantinibUC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
Expansion Cohort 5atezolizumabUC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
Expansion Cohort 6cabozantinibCRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
Expansion Cohort 7atezolizumabStage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
Expansion Cohort 9atezolizumabStage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 8cabozantinibStage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
Expansion Cohort 9cabozantinibStage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 10atezolizumabRCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
Expansion Cohort 11cabozantinibTNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 11atezolizumabTNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 12atezolizumabOC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
Expansion Cohort 12cabozantinibOC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
Expansion Cohort 14atezolizumabHCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
Expansion Cohort 14cabozantinibHCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
Expansion Cohort 15atezolizumabGC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
Expansion Cohort 15cabozantinibGC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
Expansion Cohort 16atezolizumabCRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
Expansion Cohort 17atezolizumabH\&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 17cabozantinibH\&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
Expansion Cohort 18atezolizumabDTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
Expansion Cohort 18cabozantinibDTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
Expansion Cohort 19 (SAC)cabozantinibUC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
Expansion Cohort 20 (SAC)cabozantinibStage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
Expansion Cohort 21 (SAC)cabozantinibMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
Expansion Cohort 22 (SAA)atezolizumabMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
Expansion Cohort 24atezolizumabMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
Expansion Cohort 23cabozantinibMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
Expansion Cohort 24cabozantinibMetastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
Primary Outcome Measures
NameTimeMethod
Dose Escalation: MTD/Recommended DoseUp to 6 months

To determine the maximum tolerated dose (MTD) and/or recommended dose and schedule for the subsequent Expansion Stage of daily oral administration of cabozantinib in subjects with solid tumors when taken in combination with atezolizumab.

Dose Expansion: ORRUp to 31 months

To evaluate preliminary efficacy by estimating the Objective Response Rate (ORR) as assessed by the Investigator per RECIST 1.1.

Secondary Outcome Measures
NameTimeMethod
Incidence and severity of nonserious AEs and SAEs (Safety)Up to 41 months

To assess safety for the combination therapy through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs), including immune-related adverse events (irAEs).

Trial Locations

Locations (124)

Exelixis Clinical Site #51

🇺🇸

Newport Beach, California, United States

Exelixis Clinical Site #94

🇪🇸

Oviedo, Asturias, Spain

Exelixis Clinical Site #10

🇺🇸

Boston, Massachusetts, United States

Exelixis Clinical Site #67

🇺🇸

Cleveland, Ohio, United States

Exelixis Clinical Site #29

🇺🇸

Houston, Texas, United States

Exelixis Clinical Site #53

🇺🇸

Gilbert, Arizona, United States

Exelixis Clinical Site #20

🇺🇸

La Jolla, California, United States

Exelixis Clinical Site #24

🇺🇸

New Orleans, Louisiana, United States

Exelixis Clinical Site #115

🇦🇺

Gosford, New South Wales, Australia

Exelixis Clinical Site #101

🇦🇺

Camperdown, New South Wales, Australia

Exelixis Clinical Site #60

🇺🇸

Atlanta, Georgia, United States

Exelixis Clinical Site #123

🇦🇺

Randwick, New South Wales, Australia

Exelixis Clinical Site #7

🇫🇷

Paris, France

Exelixis Clinical Site #119

🇫🇷

Strasbourg, France

Exelixis Clinical Site #88

🇫🇷

La Roche-sur-Yon, Cedex 9, France

Exelixis Clinical Site #54

🇧🇪

Leuven, Belgium

Exelixis Clinical Site #84

🇮🇹

Meldola, FC, Italy

Exelixis Clinical Site #103

🇮🇹

Milano, Italy

Exelixis Clinical Site #4

🇮🇹

Milano, Italy

Exelixis Clinical Site #92

🇫🇷

Bordeaux, France

Exelixis Clinical Site #93

🇫🇷

Brest, France

Exelixis Clinical Site #56

🇩🇪

Düsseldorf, Nordrhein-Westfalen, Germany

Exelixis Clinical Site #87

🇫🇷

CAEN Cedex 05, France

Exelixis Clinical Site #97

🇫🇷

Lille, France

Exelixis Clinical Site #89

🇫🇷

Lyon Cedex 08, France

Exelixis Clinical Site #38

🇺🇸

Camden, New Jersey, United States

Exelixis Clinical Site #82

🇫🇷

Saint-Grégoire, France

Exelixis Clinical Site #14

🇺🇸

Charlottesville, Virginia, United States

Exelixis Clinical Site #36

🇩🇪

Tübingen, Germany

Exelixis Clinical Site #108

🇮🇹

Milano, Italy

Exelixis Clinical Site #91

🇪🇸

Elche, Alicante, Spain

Exelixis Clinical Site #17

🇺🇸

Rochester, Minnesota, United States

Exelixis Clinical Site #110

🇮🇹

Roma, Italy

Exelixis Clinical Site #25

🇮🇹

Milano, Italy

Exelixis Clinical Site #61

🇺🇸

Las Vegas, Nevada, United States

Exelixis Clinical Site #6

🇺🇸

Oklahoma City, Oklahoma, United States

Exelixis Clinical Site #2

🇺🇸

Salt Lake City, Utah, United States

Exelixis Clinical Site #71

🇺🇸

Oklahoma City, Oklahoma, United States

Exelixis Clinical Site #3

🇺🇸

Detroit, Michigan, United States

Exelixis Clinical Site #18

🇺🇸

Phoenix, Arizona, United States

Exelixis Clinical Site #63

🇺🇸

San Antonio, Texas, United States

Exelixis Clinical Site #111

🇪🇸

Madrid, Spain

Exelixis Clinical Site #1

🇺🇸

Duarte, California, United States

Exelixis Clinical Site #46

🇺🇸

Los Angeles, California, United States

Exelixis Clinical Site #62

🇺🇸

Santa Monica, California, United States

Exelixis Clinical Site #21

🇺🇸

Stanford, California, United States

Exelixis Clinical Site #42

🇺🇸

New Haven, Connecticut, United States

Exelixis Clinical Site #34

🇺🇸

Denver, Colorado, United States

Exelixis Clinical Site #50

🇺🇸

Denver, Colorado, United States

Exelixis Clinical Site #48

🇺🇸

Washington, District of Columbia, United States

Exelixis Clinical Site #16

🇺🇸

Jacksonville, Florida, United States

Exelixis Clinical Site #76

🇺🇸

Tampa, Florida, United States

Exelixis Clinical Site #79

🇺🇸

Atlanta, Georgia, United States

Exelixis Clinical Site #32

🇺🇸

Harvey, Illinois, United States

Exelixis Clinical Site #23

🇺🇸

Fairway, Kansas, United States

Exelixis Clinical Site #57

🇺🇸

Lexington, Kentucky, United States

Exelixis Clinical Site #65

🇺🇸

Bolivar, Missouri, United States

Exelixis Clinical Site #43

🇺🇸

Kansas City, Missouri, United States

Exelixis Clinical Site #35

🇺🇸

Omaha, Nebraska, United States

Exelixis Clinical Site #59

🇺🇸

Omaha, Nebraska, United States

Exelixis Clinical Site #27

🇺🇸

East Brunswick, New Jersey, United States

Exelixis Clinical Site #31

🇺🇸

New Brunswick, New Jersey, United States

Exelixis Clinical Site #11

🇺🇸

New York, New York, United States

Exelixis Clinical Site #37

🇺🇸

Bronx, New York, United States

Exelixis Clinical Site #40

🇺🇸

East Setauket, New York, United States

Exelixis Clinical Site #49

🇺🇸

Columbus, Ohio, United States

Exelixis Clinical Site #102

🇺🇸

Portland, Oregon, United States

Exelixis Clinical Site #45

🇺🇸

Portland, Oregon, United States

Exelixis Clinical Site #15

🇺🇸

Philadelphia, Pennsylvania, United States

Exelixis Clinical Site #64

🇺🇸

Kettering, Ohio, United States

Exelixis Clinical Site #41

🇺🇸

Bethlehem, Pennsylvania, United States

Exelixis Clinical Site #66

🇺🇸

Pittsburgh, Pennsylvania, United States

Exelixis Clinical Site #95

🇺🇸

Charleston, South Carolina, United States

Exelixis Clinical Site #55

🇺🇸

Philadelphia, Pennsylvania, United States

Exelixis Clinical Site #26

🇺🇸

Dallas, Texas, United States

Exelixis Clinical Site #13

🇺🇸

Dallas, Texas, United States

Exelixis Clinical Site #114

🇺🇸

Fort Worth, Texas, United States

Exelixis Clinical Site #44

🇺🇸

Houston, Texas, United States

Exelixis Clinical Site #39

🇺🇸

Houston, Texas, United States

Exelixis Clinical Site #33

🇺🇸

Lubbock, Texas, United States

Exelixis Clinical Site #30

🇺🇸

Blacksburg, Virginia, United States

Exelixis Clinical Site #112

🇦🇺

North Ryde, New South Wales, Australia

Exelixis Clinical Site #98

🇦🇺

Albury, New South Wales, Australia

Exelixis Clinical Site #99

🇦🇺

St Albans, Victoria, Australia

Exelixis Clinical Site #69

🇫🇷

Le Mans, France

Exelixis Clinical Site #52

🇧🇪

Gent, Belgium

Exelixis Clinical Site #8

🇫🇷

Villejuif, Cedex, France

Exelixis Clinical Site #104

🇫🇷

Nice Cedex 02, France

Exelixis Clinical Site #80

🇫🇷

Nîmes Cedex 09, France

Exelixis Clinical Site #68

🇫🇷

Paris, France

Exelixis Clinical Site #72

🇫🇷

Paris, France

Exelixis Clinical Site #109

🇫🇷

Marseille, France

Exelixis Clinical Site #78

🇫🇷

Paris, France

Exelixis Clinical Site #107

🇫🇷

Suresnes, France

Exelixis Clinical Site #105

🇫🇷

Vandoeuvre les nancy, France

Exelixis Clinical Site #47

🇮🇹

Rozzano, Milano, Italy

Exelixis Clinical Site #74

🇪🇸

Santiago De Compostela, A Coruña, Spain

Exelixis Clinical Site #85

🇮🇹

Napoli, Italy

Exelixis Clinical Site #121

🇮🇹

Pavia, Italy

Exelixis Clinical Site #70

🇪🇸

Palma De Mallorca, Baleares, Spain

Exelixis Clinical Site #113

🇪🇸

Badalona, Barcelona, Spain

Exelixis Clinical Site #116

🇪🇸

Sabadell, Barcelona, Spain

Exelixis Clinical Site #96

🇪🇸

Jeréz De La Frontera, Cádiz, Spain

Exelixis Clinical Site #58

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #90

🇪🇸

Pamplona, Navarra, Spain

Exelixis Clinical Site #117

🇪🇸

La Laguna, Santa Cruz De Tenerife, Spain

Exelixis Clinical Site #75

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #86

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #28

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #9

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #83

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #73

🇪🇸

Barcelona, Spain

Exelixis Clinical Site #118

🇪🇸

Girona, Spain

Exelixis Clinical Site #77

🇪🇸

Madrid, Spain

Exelixis Clinical Site #106

🇪🇸

Madrid, Spain

Exelixis Clinical Site #5

🇪🇸

Madrid, Spain

Exelixis Clinical Site #22

🇪🇸

Madrid, Spain

Exelixis Clinical Site #81

🇪🇸

Madrid, Spain

Exelixis Clinical Site #122

🇬🇧

Middlesex, England, United Kingdom

Exelixis Clinical Site #120

🇬🇧

Preston, England, United Kingdom

Exelixis Clinical Site #100

🇪🇸

Málaga, Spain

Exelixis Clinical Site #124

🇬🇧

Cardiff, Wales, United Kingdom

Exelixis Clinical Site #19

🇬🇧

London, United Kingdom

Exelixis Clinical Site #12

🇳🇱

Nijmegen, Gelderland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy